瑞普生物（300119）公告，预计2025年上半年净利润为2.44亿元–2.77亿元，比上年同期的1.63亿元增长 50%–70%。 ...

[I. Current Period Performance Forecast](index=1&type=section&id=I.%20Current%20Period%20Performance%20Forecast) This section outlines the company's estimated financial performance for the first half of 2025, projecting significant growth in net profit [1. Forecast Period](index=1&type=section&id=1.%20Forecast%20Period) This performance forecast covers the semi-annual operating results from January 1, 2025, to June 30, 2025 - The performance forecast period is from January 1, 2025, to June 30, 2025[3](index=3&type=chunk) [2. Performance Forecast: Upward Trend](index=1&type=section&id=2.%20Performance%20Forecast%3A%20Upward%20Trend) The company anticipates substantial growth in net profit attributable to shareholders and net profit after non-recurring gains/losses for H1 2025 2025 Semi-Annual Performance Forecast | Item | Current Period (Estimated) | Prior Year Period (Restated) | Year-on-Year Growth | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Shareholders of the Listed Company | Profit: **RMB 244.16 million – RMB 276.72 million** | Profit: RMB 162.7783 million | **50% – 70%** | | Net Profit Attributable to Shareholders of the Listed Company After Non-Recurring Gains and Losses | Profit: **RMB 181.75 million – RMB 209.72 million** | Profit: RMB 139.8102 million | **30% – 50%** | - Prior period financial indicators have been restated in the "2024 Annual Report" to reflect the impact of business combinations under common control[3](index=3&type=chunk) [II. Communication with Accounting Firm](index=1&type=section&id=II.%20Communication%20with%20Accounting%20Firm) This section clarifies the current audit status of the preliminary performance forecast data [1. Audit Status Explanation](index=1&type=section&id=1.%20Audit%20Status%20Explanation) The performance forecast data represents preliminary calculations by the company's finance department and has not yet been audited by an accounting firm - The data related to this performance forecast is a preliminary calculation by the company's finance department and has not been audited by an accounting firm[4](index=4&type=chunk) [III. Explanation of Performance Changes](index=1&type=section&id=III.%20Explanation%20of%20Performance%20Changes) This section details the key factors driving the company's performance growth, including strategic initiatives and non-recurring items [1. Drivers of Operating Performance Growth](index=1&type=section&id=1.%20Drivers%20of%20Operating%20Performance%20Growth) The company achieved both volume and profit growth by driving technological innovation, focusing on high-potential new businesses, and implementing lean management - The company drives high-quality development through technological innovation, focusing on customer needs with "scenario-based disease research + systematic solutions" to lead industry technological progress[5](index=5&type=chunk)[6](index=6&type=chunk) - Leveraging a full product line system, the company builds a model of "high-quality products + disease monitoring and early warning + standardized epidemic control solutions + management services," innovating strategic collaborations with large-scale farming enterprises to increase market share and key account penetration in the poultry and livestock animal health sectors[6](index=6&type=chunk) - Focusing on high-potential segments such as pet medical care and overseas markets, new businesses achieved substantial growth, accelerating overseas product registration, channel development, talent recruitment, and international brand building, thereby speeding up the implementation of its global expansion strategy[6](index=6&type=chunk) - Implementing a "value-driven core" full-chain closed-loop operational management system, with lean management as a key tool, the company reshapes its profitability model through lean cost reduction and value innovation, improving production efficiency and reducing costs to achieve both volume and profit growth[6](index=6&type=chunk) [2. Composition of Non-Recurring Gains and Losses](index=2&type=section&id=2.%20Composition%20of%20Non-Recurring%20Gains%20and%20Losses) Non-recurring gains and losses for H1 2025 primarily stem from fair value changes in non-current financial assets, wealth management products, investment income, and government subsidies - Non-recurring gains and losses in H1 2025 primarily include fair value changes from non-current financial assets and wealth management products, investment income, and government subsidies[6](index=6&type=chunk) [3. Strategic Outlook](index=2&type=section&id=3.%20Strategic%20Outlook) The company will continue its "product leadership, system refinement" strategy, building a technological moat with new quality productive forces for high-quality development - The company will adhere to the "product leadership, system refinement" strategic path, building a technological moat with new quality productive forces, pursuing high-quality development, and steadfastly moving towards the goal of becoming a world-class high-tech biological enterprise[7](index=7&type=chunk) - The ongoing deep adjustment in the animal health industry will continue to clear out excess capacity, with industry profitability centralizing towards leading players and the value chain continuously upgrading[7](index=7&type=chunk) [IV. Risk Warning and Other Related Information](index=2&type=section&id=IV.%20Risk%20Warning%20and%20Other%20Related%20Information) This section provides a crucial warning regarding the preliminary nature of the performance forecast and advises investor caution [1. Risk Warning](index=2&type=section&id=1.%20Risk%20Warning) This performance forecast is a preliminary, unaudited estimate; investors should exercise caution, as final financial data will be based on the company's semi-annual report - This performance forecast is a preliminary calculation by the company's finance department and has not been audited by an accounting firm; specific financial data will be subject to the company's disclosed 2025 semi-annual report[8](index=8&type=chunk) - Investors are kindly requested to make prudent decisions and be aware of investment risks[8](index=8&type=chunk)

Investment Rating - The report maintains a "Buy" rating for the agriculture, forestry, animal husbandry, and fishery sector [4] Core Viewpoints - Recent policy guidance has led to a rapid decline in post-slaughter weight, allowing for a rebalancing of volume and price, with positive expectations for pig prices [3] - The long-term perspective indicates that the bottom of the production capacity cycle is becoming clearer, suggesting a potential long-term profit upturn for the sector [3] - The report highlights investment opportunities in various segments, including pig farming, feed, and planting chains, as well as the pet food sector [3] Summary by Sections Pig Farming Sector - In June, 13 listed pig companies collectively slaughtered 16.2681 million pigs, a month-on-month increase of 2.65% and a year-on-year increase of 47.55% [2][13] - The average selling price of pigs decreased by approximately 3% month-on-month and about 20% year-on-year, with prices ranging from 13.23 to 15.57 yuan/kg [14][15] - The average weight of slaughtered pigs in June was 125.06 kg, down 0.77 kg from May, indicating a trend towards reducing weight [17] Market Dynamics - The national average price for live pigs was 14.81 yuan/kg as of July 11, reflecting a week-on-week decline of 3.52% [28] - The demand for pork is weakening due to high temperatures affecting consumption and rising storage costs, leading to a gradual loosening of supply-demand dynamics [28] Investment Recommendations - The report recommends focusing on leading companies such as Muyuan Foods, Wens Foodstuff, and Juxing Agriculture, as well as companies in the feed and animal health sectors like Haida Group and Ruipu Biological [3] - In the planting chain, opportunities are highlighted for companies like Suqian Agricultural Development and Beidahuang [3] Other Segments - The pet food industry is experiencing growth, with increasing recognition of domestic brands and continuous growth of leading companies [3]

证券代码：300119 证券简称：瑞普生物 公告编号：2025-054 瑞普生物股份有限公司 关于控股股东及其一致行动人持股比例因公司注销回购股份 被动增加触及 1%的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、特别提示： 1、本次权益变动系瑞普生物股份有限公司（以下简称"公司"）回购注销 2022 年限制性股票激励计划部分股份，公司总股本由 465,847,906 股减至 464,754,706 股，具体内容详见公司于 2025 年 7 月 11 日在巨潮资讯网披露的《关 于 2022 年限制性股票激励计划部分限制性股票回购注销完成工商变更登记的公 告》（公告编号：2025-053），公司控股股东李守军及其一致行动人李睿在持股 数不变的情况下，持股比例由 35.95%被动增加至 36.04%，触及 1%刻度。 2、本次权益变动前，公司控股股东李守军持有公司股份的比例为 35.95%， 其一致行动人李睿持有公司股份的比例为 0.001%，控股股东及一致行动人合计 持有公司股份的比例为 35.95%。本期权益变动后，公司控股股东李守军持有公 司股份 ...

证券代码：300119 证券简称：瑞普生物 公告编号：2025-053 瑞普生物股份有限公司 关于 2022 年限制性股票激励计划部分限制性股票 回购注销完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 法定代表人：李守军 注册资本：肆亿陆仟肆佰柒拾伍万肆仟柒佰零陆元人民币 成立日期：2001 年 8 月 2 日 经营范围：一般项目：技术服务、技术开发、技术咨询、技术交流、技术转 让、技术推广；饲料原料销售；饲料添加剂销售；消毒剂销售（不含危险化学品）； 宠物食品及用品批发；宠物食品及用品零售；专用化学产品销售（不含危险化学 1 瑞普生物股份有限公司（简称"公司"）于 2025 年 4 月 24 日召开 2024 年 年度股东大会，审议通过了《关于回购注销 2022 年限制性股票激励计划部分限 制性股票的议案》和《关于修改公司章程的议案》，同意回购注销公司 2022 年 限制性股票激励计划部分限制性股票 1,093,200 股，并相应减少公司注册资本。 注销完成后，公司总股本由 465,847,906 股减至 464,754,706 股， ...

瑞普生物股份有限公司 关于持股 5%以上股东梁武持股拟在一致行动人之间内部转让 证券代码：300119 证券简称：瑞普生物 公告编号：2025-052 的公告 股东梁武、上海阿杏投资管理有限公司-阿杏延安9号私募证券投资基金、图灵私募基 金管理（海南）有限公司-图灵麦田6号私募证券投资基金保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、瑞普生物股份有限公司（以下简称"公司""本公司"）于近日收到持 股 5%以上股东梁武先生（本人持股 23,716,898 股，占本公司总股本比例 5.10%） 的告知函，因家庭资产规划需要，计划在未来三个月内以大宗交易方式向其一致 行动人转让本公司股份 90.00 万股，占本公司总股本比例 0.19%。 2、本次股份变动属于公司持股 5%以上股东梁武及其一致行动人之间股份 的内部转让，其合计持股数量和比例未发生变化，不会导致公司控制权发生变化， 不会影响公司治理结构和持续经营。 一、股东梁武的基本情况 1、股东名称：梁武 2、持股情况：梁武本人持有本公司股份 ...

Investment Rating - The report rates the agricultural, forestry, animal husbandry, and fishery industry as "Overweight" due to expected overall profit improvement in the sector [3][4]. Core Insights - The report highlights that the profitability of pig farming is expected to improve, with a stable pig price and a significant increase in average profit per head for self-bred pigs [4]. - Poultry farming shows a mixed outlook, with white chicken prices bottoming out and yellow chicken profitability declining, while egg-laying chicks continue to experience high demand [4]. - The pet food sector is projected to maintain high growth, with leading companies showing strong online sales growth, despite a decline in exports to the U.S. due to tariffs [4]. - Animal health is recovering, with increased demand for vaccines and improved sales of veterinary preparations [4]. - The seed industry faces challenges with declining corn prices and increased competition, leading to pressure on the performance of leading seed companies [4]. Summary by Sections Pig Farming - The average price of pigs in H1 2025 is expected to be 14.80 CNY/kg, a decrease of 4.2% year-on-year, while the average profit for self-bred pigs is projected at 69.04 CNY/head, recovering from a loss of 24.82 CNY/head in H1 2024 [4]. Poultry Farming - White chicken prices are under pressure due to oversupply, with the average price for commodity broiler chicks at 2.4 CNY/bird, down 21% year-on-year. Yellow chicken prices are also declining, with the average price for Qingjiao chicken at 8.9 CNY/kg, down 19% year-on-year [4]. Pet Food - The domestic pet food market is experiencing a growth rate of 17% in online GMV for the first five months of 2025, compared to 14% in the same period of 2024. Leading companies like Guibao Pet and Zhongchong Co. show growth rates of 51% and 26%, respectively [4]. Animal Health - The demand for veterinary vaccines has increased, with a 15.8% year-on-year rise in vaccine approvals in the first five months of 2025. Prices for veterinary preparations like Tylosin and Tiamulin have increased by 39.8% and 9.3%, respectively [4]. Seed Industry - The corn seed market is under pressure due to falling corn prices and high competition, leading to a decline in seed prices and performance expectations for leading seed companies [4].

证券代码：300119 证券简称：瑞普生物 公告编号：2025-051 瑞普生物股份有限公司 关于 2022 年限制性股票激励计划部分限制性股票 回购注销完成暨股份变动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 1、本次回购注销 2022 年限制性股票激励计划已授予但尚未解除限售的限制 性股票数量合计 1,093,200 股，占回购注销前公司总股本的 0.2347%，涉及激励 对象 176 人。 2、经中国证券登记结算有限责任公司深圳分公司审核确认，公司本次部分 限制性股票注销事宜已于 2025 年 6 月 30 日办理完成。 3、注销完成后，公司股份总数由 465,847,906 股减少至 464,754,706 股。 瑞普生物股份有限公司（简称"公司"）于 2025 年 4 月 1 日召开的第五届 董事会第二十二次会议、第五届监事会第十八次会议和 2025 年 4 月 24 日召开的 2024 年年度股东大会审议通过了《关于回购注销 2022 年限制性股票激励计划部 分限制性股票的议案》和《关于修改公司章程的议案》，同意回购注销公司 ...

Investment Rating - The report maintains a "Recommended" rating for the agriculture, forestry, animal husbandry, and fishery industry [1][61]. Core Views - The report highlights that the pig price may experience a turning point due to seasonal factors and policy changes, suggesting a bottoming out phase for the sector [2][12]. - The poultry sector is seeing price declines, but there are signs of marginal improvements in the cycle [3][24]. - The animal health sector is expected to see performance recovery, and there are investment opportunities in the pet medical industry [4][35]. - The planting sector is witnessing a week-on-week rebound in grain prices [5][43]. - The feed sector is experiencing price fluctuations, with a general downward trend [6][46]. - The pet economy is thriving, with domestic brands gaining strength [7][51]. Summary by Sections Pig Industry - The average pig price is currently fluctuating between 14-15 CNY/kg, with a notable increase in average weights compared to previous years [11][12]. - The report recommends focusing on companies with low costs and strong financial health, such as Wens Foodstuffs, Muyuan Foods, and Juxing Agriculture [12][61]. Poultry Industry - The poultry prices are declining, with the white feather chicken price at 3.48 CNY/jin, showing a slight decrease [24][25]. - The report recommends companies like San Nong Development and Yisheng Livestock, while suggesting to pay attention to He Feng and Minhe Livestock [25][61]. Animal Health - The animal health sector is expected to recover, supported by the profitability of the pig farming industry [35][36]. - The pet medical market is projected to grow, with a market size of approximately 840 billion CNY, representing 28% of the pet industry [4][35]. Planting Sector - Grain prices are showing a week-on-week increase, with corn priced at 2353 CNY/ton and wheat at 2446 CNY/ton [43][44]. - The report suggests focusing on companies involved in genetically modified seeds, such as Suqian Agricultural Development and Longping High-tech [43][61]. Feed Sector - Feed prices are experiencing a downward trend, with pig feed at 3.36 CNY/kg [46][47]. - The report recommends Hai Da Group and suggests paying attention to He Feng [47][61]. Pet Industry - The pet market is expected to reach a scale of 300.2 billion CNY in 2024, with a growth rate of 7.5% [51][52]. - The report recommends companies in the pet food sector like Guobao Pet and Zhongchong Co., and in the pet medical sector, it recommends Ruipu Biological [55][61].

1、本次股东大会无变更、否决议案的情况； 2、本次股东大会以现场投票、网络投票相结合的方式召开。 一、会议召开和出席情况 证券代码：300119 证券简称：瑞普生物 公告编号：2025-050 瑞普生物股份有限公司 2025 年第三次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 瑞普生物股份有限公司（以下简称"公司"）2025年6月14日以董事会公告方式 向全体股东发出召开2025年第三次临时股东大会的通知。（公告编号：2025-048）。 本次股东大会采取现场投票、网络投票相结合的方式召开。其中现场会议于2025 年6月30日下午14:30在公司会议室召开，会议由董事长李守军先生主持；通过深圳证 券交易所系统进行网络投票的时间为2025年6月30日09:15-09:25，09:30-11:30，13:00- 15:00；通过深圳证券交易所互联网系统投票的具体时间为2025年6月30日09:15- 15:00期间的任意时间。 公司总股本465,847,906股，扣除公司股份回购专户的股份数后，公司有表决权 股份总数为455, ...